AI-Designed Antibodies That Work: 100+ Success Cases Across Targets and Modalities
Sequence-based AI design for novel and difficult targets — and what more than a hundred success cases across antibody modalities show about where it works.
The fourth episode of NAPPA Healthcare & Biopharma Insights asks a practical question of AI in antibody discovery: where has it actually worked? Claims for AI-designed biologics are easy to make and hard to verify; a track record across many targets and formats is the more useful measure.
Dr. Lurong Pan, Founder and Chief Executive Officer of Ainnocence Inc., presents sequence-based AI design for novel and difficult targets, drawing on more than a hundred success cases. The hour covers results across modalities — conventional antibodies, VHH/nanobodies, bispecifics, antibody-drug conjugates (ADCs), and more.
The session is open to NAPPA members, partners, and qualified industry guests. Register below to receive Zoom join details.
Key topics.
- ✓ Sequence-based AI design of antibodies
- ✓ Applying AI design to novel and difficult targets
- ✓ Results across antibodies, VHH/nanobodies, bispecifics, ADCs, and more
- ✓ Lessons from 100+ success cases across targets and modalities
See how sequence-based AI design approaches an antibody program.
Learn where AI design has delivered on novel and hard-to-drug targets.
Compare results across antibodies, VHH/nanobodies, bispecifics, and ADCs.
Hear what more than a hundred success cases say about what works in practice.
This event has already taken place.
Registration closed on Saturday, October 17, 2026. Thanks to everyone who joined us live. Check the Events page for upcoming episodes in the NAPPA Healthcare & Biopharma Insights series.